Unknown

Dataset Information

0

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.

ABSTRACT: An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium-glucose cotransporter 2 inhibitor tofogliflozin for up to 24?weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log10 -transformed urinary N-acetyl-?-D-glucosaminidase ratio were significantly correlated with the reduction in serum UA levels at both 4 and 24?weeks in multivariate analysis (respectively, P??8.6%) and lowest in the group with the lowest baseline HbA1c level (quartile 1; HbA1c???7.4%). The decrease in serum UA levels was greatest in the quartile 1 group and lowest in the quartile 4 group. In most groups, the maximum decrease in serum UA levels was seen in the first 4?weeks, while the maximum decrease in HbA1c was seen at week 24. Thus, serum UA levels were significantly decreased in patients with moderate HbA1c levels.

SUBMITTER: Ouchi M 

PROVIDER: S-EPMC5887894 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium-glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log<sub>10</sub> -transformed urinary N-acetyl-β-D-glucosaminidase ratio were significantly correlated with the reduction in serum UA levels at both 4 and 24 weeks in multivariat  ...[more]